Desheng Weng

机构：Sun Yat-sen University, Sun Yat-sen University Cancer Center

发表论文 79 篇 · 总被引 2199 次 · h-index 27

代表论文

• CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype (2022 · Journal for ImmunoTherapy of Cancer · 被引 167)
• Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A∗02:01 patients with advanced soft tissue sarcoma (2023 · Cell Reports Medicine · 被引 53)
• CMTM6 inhibits tumor growth and reverses chemoresistance by preventing ubiquitination of p21 in hepatocellular carcinoma (2022 · Cell Death and Disease · 被引 45)
• Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma (2023 · BMC Medicine · 被引 41)
• XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial (2024 · Signal Transduction and Targeted Therapy · 被引 35)
• Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial (2023 · EClinicalMedicine · 被引 34)